Category: imidazoles-derivatives

Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomas was written by Dimou, Maria;Papageorgiou, Sotirios G.;Stavroyianni, Niki;Katodritou, Eirini;Tsirogianni, Maria;Kalpadakis, Christina;Banti, Anastasia;Arapaki, Maria;Iliakis, Theodoros;Bouzani, Maria;Verrou, Eugenia;Spanoudakis, Emmanouil;Giannouli, Stavroula;Marinakis, Theodoros;Mandala, Evdokia;Mparmparousi, Despoina;Sachanas, Sotirios;Dalekou-Tsolakou, Maria;Hatzimichael, Eleftheria;Vadikolia, Chryssa;Violaki, Vasiliki;Poziopoulos, Christos;Tsirkinidis, Pantelis;Chatzileontiadou, Sofia;Vervessou, Elissavet;Ximeri, Maria;Sioni, Anastasia;Konstantinidou, Pavlina;Kyrtsonis, Marie-Christine;Siakantaris, Marina P.;Angelopoulou, Maria K.;Pappa, Vassiliki;Konstantopoulos, Kostas;Panayiotidis, Panayiotis;Vassilakopoulos, Theodoros P.. And the article was included in Hematological Oncology in 2021.Reference of 16506-27-7 The following contents are mentioned in the article:

Transplant-ineligible relapsed/refractory (rr) diffuse large B-cell lymphoma (DLBCL) patients represent an unmet medical need. Polatuzumab vedotin (Pola), an anti-CD79b antibody-drug-conjugate (ADG), with bendamustine- rituximab(BR) has recently gained approval for these patients, both in the USA and Europe, based on the GO29365 phase IIb trial. Real-life data with Pola are extremely limited. We report the outcomes of 61 Greek patients, who received Pola-(B)R mainly within a compassionate use program. Treatment was given for up to six 21-day cycles. Bendamustine was omitted in three cases due to previous short-lived responses. Fourty-nine rrDLBCL(efficacy cohort-EC) and 58 rr aggressive B-NHL (safety cohort-SC) patients received at least 1 Pola-BR cycle. Twenty-one (43%) patients of the EC responded with 12/49 (25%) CR and 9/49 (18%) PR as best response. Median progression-free survival, overall survival and duration of response were 4.0, 8.5, and 8.5 mo resp., while 55% of patients experienced a grade � adverse event, mainly hematol. Treatment discontinuations and death during treatment were mainly due to disease progression. Twenty-two (41%) patients received further treatment; 11/22 are still alive, including one after CAR-T cells, and two after stem cell transplantation. Our data confirm that Pola-BR is a promising treatment for rrDLBCL patients, inducing an adequate response rate with acceptable toxicity. Pola-BR could be used as bridging therapy before further consolidative treatments. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Reference of 16506-27-7).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Imidazole has been usedin the lysis, wash and elution buffer for the purification of histidine tagged Sonic Hedgehog(shh-N) protein, in elution buffer in stepwise gradient for the purification of histidine tagged aldo keto reductases using nickel affinity chromatography, as a component of homogenization buffer for the purification of phagosomal compartments from dendritic cells.Reference of 16506-27-7

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Optimizing first line 7-day standard triple therapy for Helicobacter pylori eradication: Prolonging treatment or adding bismuth: which is better? was written by Leow, Alex H.-R.;Azmi, Ahmad N.;Loke, Mun-Fai;Vadivelu, Jamuna;Graham, David Y.;Goh, Khean-Lee. And the article was included in Journal of Digestive Diseases in 2018.Category: imidazoles-derivatives The following contents are mentioned in the article:

The 7-day standard triple therapy (STT) gives unacceptablly low eradication rates of Helicobacter pylori (H. pylori). We aimed to examine whether extending STT from 7 days to 14 days or adding a bismuth compound to a 7-day STT would result in better eradication rates. H. pylori-pos. patients were assigned to Group A (7-day STT; rabeprazole 20 mg twice daily, amoxicillin 1 g twice daily, and clarithromycin 500 mg twice daily, for 7 days), Group B (7-day STT with bismuth; rabeprazole 20 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily and bismuth subcitrate 240 mg twice daily, for 7 days) and Group C (14-day STT; rabeprazole 20 mg twice daily, amoxicillin 1 g twice daily, and clarithromycin 500 mg twice daily for 14 days). Eradication was tested using ¹³C-UBT at least 4 wk after the completion of therapy. A total of 364 patients were recruited. In the intention-to-treat anal., eradication rates were 79.3% (96/121; 95% confidence interval [CI] 71.3-85.6%) for 7-day STT, 81.7% (98/120; 95% CI 73.8-87.6%) for 7-day STT with bismuth, and 88.6% (109/123; 95% CI 81.8-93.1%) for 14-day STT, resp. Statistical significance was achieved between the 7-day and the 14-day STT treatment (P = 0.048). Adding bismuth to the 7-day STT did not result in an increase in the eradication rate. Extending the STT to 14 days, however, achieved a significantly higher eradication rate. Nevertheless, this did not achieve the targeted 90% eradication rate on intention-to-treat anal. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Category: imidazoles-derivatives).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Imidazole has been usedin the lysis, wash and elution buffer for the purification of histidine tagged Sonic Hedgehog(shh-N) protein, in elution buffer in stepwise gradient for the purification of histidine tagged aldo keto reductases using nickel affinity chromatography, as a component of homogenization buffer for the purification of phagosomal compartments from dendritic cells.Category: imidazoles-derivatives

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Autoimmune hemolytic anemia: causes and consequences was written by Fattizzo, B.;Barcellini, W.. And the article was included in Expert Review of Clinical Immunology in 2022.Recommanded Product: 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid The following contents are mentioned in the article:

A review. Autoimmune hemolytic anemia (AIHA) is classified according to the direct antiglobulin test (DAT) and thermal characteristics of the autoantibody into warm and cold forms, and in primary vs. secondary depending on the presence of associated conditions. AIHA displays a multifactorial pathogenesis, including genetic (association with congenital conditions and certain mutations), environmental (drugs, infections, including SARS-CoV-2, pollution, etc.), and miscellaneous factors (solid/hematol. neoplasms, systemic autoimmune diseases, etc.) contributing to tolerance breakdown. Several mechanisms, such as autoantibody production, complement activation, monocyte/macrophage phagocytosis, and bone marrow compensation are implicated in extra-/intravascular hemolysis. Treatment should be differentiated and sequenced according to AIHA type (i.e. steroids followed by rituximab for warm, rituximab alone or in association with bendamustine or fludarabine for cold forms). Several new drugs targeting B-cells/plasma cells, complement, and phagocytosis are in clin. trials. Finally, thrombosis and infections may complicate disease course burdening quality of life and increasing mortality. Beyond warm and cold AIHA, a gray-zone still exists including mixed and DAT neg. forms representing an unmet need. AIHA management is rapidly changing through an increasing knowledge of the pathogenic mechanisms, the refinement of diagnostic tools, and the development of novel targeted and combination therapies. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Recommanded Product: 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. The solubility of imidazoles in ethers is lower than that in alcohols and decreases with increasing chain length of the ethers . In contrast, the solubility of benzimidazoles in alcohols (C3–C6) is higher than in water and generally decreases with a Imidazole is incorporated into many important biological compounds. The most pervasive is the amino acid histidine, which has an imidazole side-chain. Histidine is present in many proteins and enzymes, e.g. by binding metal cofactors, as seen in hemoglobin.Recommanded Product: 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Study on mechanism of ionic liquid for methane plasma conversion using spectra method was written by Zhang, Xiu-ling;Zhou, Qian;Di, Lan-bo;Yu, Miao. And the article was included in Guangpuxue Yu Guangpu Fenxi in 2012.Recommanded Product: 1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate The following contents are mentioned in the article:

C₆MIMBF₄, C₆MIMCF₃COO and C₆MIMHSO₄ were introduced into a d.c. discharge plasma system resp. for methane conversion. The kinds of active species and relative intensity of spectral peaks were detected through online spectrum diagnosis technique of optical emission spectroscopy. Mechanism of ionic liquid for methane conversion in gas-liquid plasma was investigated. The results showed that a spatially and temporally stable gas-liquid interface was obtained in ionic liquid incorporated plasma system. With introduction of ionic liquid, methane conversion and C₂ hydrocarbons yields increased. The C₂ hydrocarbon selectivity greatly increased when C₆MIMCF₃COO and C₆MIMBF₄ were introduced to the plasma, and decreased when C₆MIMHSO₄ was used. Active species like C, C₂, C₃, CH and H were detected in gas-liquid plasma system of methane discharge. Compared with the absence of ionic liquid in the plasma system, the relative intensity of spectral peaks of most active species increased when ionic liquid was introduced into the plasma system. ¹H NMR results showed that the structure of ionic liquid kept stable during plasma discharge progress. Those indicated that ionic liquid could improve the plasma discharge intensity. At the same time, ionic liquid showed good catalytic activity in gas-liquid surface reaction. This study involved multiple reactions and reactants, such as 1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate (cas: 478935-29-4Recommanded Product: 1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate).

1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate (cas: 478935-29-4) belongs to imidazole derivatives. Imidazole is the basic core of some natural products such as histidine, purine, histamine and DNA based structures, etc. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. The pharmacophore of imidazole exists in bioactive compounds including amino acids, plant growth regulators and therapeutic agents.n increase of the alkyl chain length of the alcohols. Recommanded Product: 1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Nitrolysis of hexamethylenetetramine in presence of ionic liquids was written by Wang, Nai;Shi, Yu;Yang, Hong-wei;Chen, Guang-bin;Lu, Chun-xu. And the article was included in Hanneng Cailiao in 2011.Safety of 1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate The following contents are mentioned in the article:

Direct nitrolysis of hexamethylenetetramine catalyzed by ionic liquids was studied. The effects of dosage of ionic liquid and different ionic liquids on the nitrolysis were investigated in the systems of 95% nitric acid and nitrogen pentoxide/nitric acid. In the system of 95% nitric acid, [Hmim]NO₃ shows the best catalytic activity in all of ionic liquids screened. The optimal reaction condition is 1.5mol% ionic liquid loading, 12 : 1 of quality ratio of 95% nitric acid to hexamethylenetetramine and 90 min of reaction time at -5-0 °C. 1,3,5-Tri-nitroperhydro-1,3,5-triazine can be obtained in yield of 75.9% using ionic liquid as catalyst under optimized condition, while 1,3,5-tri-nitroperhydro-1,3,5-triazine can be generated in lower yield of 68.3% without adding ionic liquid In the system of nitrogen pentoxide/nitric acid, [Bmim]BF₄ shows the best catalytic activity. The optimal reaction conditions are 5mol% ionic liquid loading, 9 : 1 of mass ratio of 100% nitric acid to hexamethylenetetramine, 2 : 1 of quality ratio of 100% hexamethylenetetramine to nitrogen pentoxide and 60 min of reaction time at -5-0 °C. Under optimized conditions, 77.6% yield of 1,3,5-tri-nitroperhydro-1,3,5-triazine can be obtained without adding ionic liquid, while yield of 1,3,5-tri-nitroperhydro-1,3,5-triazine can be improved to 85.4% using ionic liquid as catalyst. It indicates that ionic liquids have observably catalytic activity on the direct nitrolysis of hexamethylenetetramine. This study involved multiple reactions and reactants, such as 1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate (cas: 478935-29-4Safety of 1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate).

1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate (cas: 478935-29-4) belongs to imidazole derivatives. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Imidazole has become an important synthon in the development of new drugs. Imidazole based anticancer drug find applications in cancer chemotherapy. It is used as buffer component for purification of the histidine tagged recombinant proteins in immobilized metal-affinity chromatography (IMAC).Safety of 1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Characteristics of cutaneous adverse drug reactions caused by triple-combination drug therapy used for Helicobacter pylori eradication was written by Kikuchi, Sota;Nobeyama, Yoshimasa;Saeki, Hidehisa;Asahina, Akihiko. And the article was included in Journal of Dermatology in 2020.Name: Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide The following contents are mentioned in the article:

Cutaneous adverse drug reactions (cADR) should be appropriately managed in drug administration. LANSAP, Rabecure and VONOSAP are currently used for Helicobacter pylori eradication therapy. Here, we examined the characteristics of cADR caused by these drugs using data from the Pharmaceuticals and Medical Devices Agency (PMDA). Periods subject to analyses were set according to the year of release of these drugs: (i) from 2008 to 2017 for LANSAP; (ii) from 2014 to 2017 for Rabecure; and (iii) 2017 for VONOSAP. Among all cADR reported to the PMDA, those attributed to LANSAP, Rabecure and VONOSAP accounted for 2.3%, 1.0% and 3.6% of cases, resp. cADR occurred in patients aged in their 20s or older, with the oldest patients aged in their 60s. Numbers of male and female patients were 28 and 70 for LANSAP, eight and 14 for Rabecure and three and 16 for VONOSAP, resp. Statistical analyses revealed significant sex differences for LANSAP (P = 0.022) and VONOSAP (P = 0.012), but not for Rabecure (P = 0.729). LANSAP, Rabecure or VONOSAP caused erythema multiforme in the largest population of patients and Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) in three patients. Ratios of SJS/TEN were 0.0-5.3% for LANSAP, Rabecure or VONOSAP, but 11.5-44.8% for the corresponding single constituent drugs other than vonoprazan. In conclusion, female sex appears to represent a risk factor for cADR attributed to H. pylori eradication therapy using LANSAP or VONOSAP, although H. pylori eradication therapy without these drugs rarely causes severe cADR. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Name: Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Imidazole is a heterocyclic compound with a five-membered planar ring. It is amphoteric and highly polar. The pharmacophore of imidazole exists in bioactive compounds including amino acids, plant growth regulators and therapeutic agents.n increase of the alkyl chain length of the alcohols. Name: Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL-a matched cohort analysis was written by Avivi, Irit;Perry, Chava;Segman, Yafit;Amit, Odelia;Bar-On, Yaeli;Katz, Ofrat Beyer;Gold, Ronit;Ribakovsky, Elena;Avigdor, Abraham;Vainstein, Vladimir;Goldschmidt, Neta;Ringelstein-Harlev, Shimrit;Horowitz, Netanel A.;Gutwein, Odit;Gurion, Ronit;Itchaki, Gilad;Abadi, Uri;Nemets, Anatoly;Sofer, Orit;Vezker, Miri;Tadmor, Tamar;Dally, Najib;Filanovsky, Kalman;Leiba, Merav;Sarid, Nadav;Benyamini, Noam;Luttwak, Efrat;Herishanu, Yair;Ram, Ron. And the article was included in Annals of Hematology in 2022.Product Details of 16506-27-7 The following contents are mentioned in the article:

Polatuzumab (Pola)-based regimens and chimeric antigen receptor T (CAR T) cells provide superior outcome compared to conventional chemoimmunotherapy in patients with relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL). Choosing between these strategies remains controversial. The efficacy of CAR T vs. Pola-rituximab(R) /Pola-bendamustine(B)-R in R/R DLBCL patients after failing ≥2 lines of treatment was compared in a retrospective, ‘real-world’ study. Propensity score matching, for age, lymphoma category (de-novo/transformed), number of prior lines, Eastern Cooperative Oncol. Group performance status and lactate dehydrogenase level, was applied to control for differences in patients’ characteristics. Response rate, progression-free survival (PFS) and overall survival (OS) were analyzed. A total of 82 patients, treated with CAR T (n = 41) or Pola-based regimens (n = 41), were included. No treatment-related deaths occurred with CAR T vs. 3 (7.3%) with Pola. The overall and complete response rates were 83% and 58% with CAR T vs. 66% and 44% with Pola-based-regimens (p = 0.077 and p = 0.18, resp.). At a median follow-up of 9 mo (range 1-19.2) and 16 mo (range 0.7-25.3) for the CAR T and Pola arm resp., the median PFS has not been reached for CAR T vs. 5.6 mo for Pola (95% CI 3.6-7.6, p = 0.014). Median OS has not been reached for CAR T vs. 10.8 mo (95% CI 2.2-19.4) for Pola (p = 0.026). To conclude, in a real-world setting, treatment with CAR T achieved superior PFS and OS compared to Pola-based regimens in patients with R/R DLBCL. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Product Details of 16506-27-7).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is a heterocyclic compound with a five-membered planar ring. It is amphoteric and highly polar. Imidazole has been usedin the lysis, wash and elution buffer for the purification of histidine tagged Sonic Hedgehog(shh-N) protein, in elution buffer in stepwise gradient for the purification of histidine tagged aldo keto reductases using nickel affinity chromatography, as a component of homogenization buffer for the purification of phagosomal compartments from dendritic cells.Product Details of 16506-27-7

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Coadministration with bendamustine restores the antitumor activity of obinutuzumab in obinutuzumab-resistant tumors was written by Yamashita-Kashima, Yoriko;Yorozu, Keigo;Fujimura, Takaaki;Kawasaki, Natsumi;Kurasawa, Mitsue;Yoshiura, Shigeki;Harada, Naoki;Kondoh, Osamu;Yoshimura, Yasushi. And the article was included in International Journal of Hematology in 2022.COA of Formula: C16H21Cl2N3O2 The following contents are mentioned in the article:

The glycoengineered, humanized anti-CD20 antibody obinutuzumab is indicated for previously untreated or relapsed/refractory CD20-pos. follicular lymphoma (FL). However, the effectiveness of obinutuzumab retreatment in relapsed/refractory FL after prior obinutuzumab-containing therapy is unclear. To address this issue, we investigated the antitumor activity of obinutuzumab plus bendamustine in obinutuzumab-resistant tumors established from a human non-Hodgkin lymphoma xenograft model. Obinutuzumab-resistant tumors (SU-DHL-4-OR-18-8) were established from an SU-DHL-4 xenograft model by repeated administration of obinutuzumab. Antitumor activity was evaluated based on tumor volume after treatment with obinutuzumab on Day 1, 8, and 15 and/or bendamustine on Day 1 and 2. Intratumoral natural killer (NK) cells/macrophages were evaluated by immunohistochem. and flow cytometry. In SU-DHL-4-OR-18-8 xenografted tumors, intratumoral NK cells/macrophages after obinutuzumab treatment were significantly decreased compared with parent tumors on Day 4. The endoplasmic reticulum stress sensor phospho-IRE1 was also decreased. In SU-DHL-4-OR-18-8 tumors, bendamustine treatment increased phospho-IRE1 on Day 4 and intratumor NK cells/macrophages on Day 10. Obinutuzumab combined with bendamustine significantly increased antitumor activity compared with each single agent on Day 29, with an increase in chemoattractant CCL6 expression on Day 10. Coadministration of bendamustine in obinutuzumab retreatment may be effective against obinutuzumab-resistant tumors. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7COA of Formula: C16H21Cl2N3O2).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Imidazole has become an important synthon in the development of new drugs. Imidazole is incorporated into many important biological compounds. The most pervasive is the amino acid histidine, which has an imidazole side-chain. Histidine is present in many proteins and enzymes, e.g. by binding metal cofactors, as seen in hemoglobin.COA of Formula: C16H21Cl2N3O2

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Probing interfacial behaviors of Bronsted acidic ionic liquids improved isobutane alkylation with C4 olefin catalyzed by sulfuric acid was written by Sun, Weizhen;Zheng, Weizhong;Cao, Piao;Zhao, Ling. And the article was included in Chemical Engineering Journal (Amsterdam, Netherlands) in 2019.Related Products of 478935-29-4 The following contents are mentioned in the article:

The interfacial microenvironments between catalysts and C4 hydrocarbons for the isobutane alkylation is of vital importance to producing high-quality alkylate. In the present work, the interfacial properties between Bronsted acidic ionic liquids (BILs)/H₂SO₄ and C4 mixtures, as well as between the cationic and anionic surfactants/H₂SO₄ and C4 mixtures were investigated using mol. dynamic (MD) simulations, in which BILs share different alkyl chain length on cations with or without a sulfonic acid group. It indicated both BILs and surfactants can enhance the H₂SO₄/C4 reactants interfacial properties and facilitate C4 reactants dissolution, contributing to a better catalytic performance. The enhancement of the interfacial properties can be ascribed into the stronger d. enrichment and perpendicular behaviors of the longer alkyl chains at the interface. Compared to non-SFILs, sulfonic-acid-functionalized Bronsted acidic ionic liquids (SFILs) can facilitate a higher dissolution of isobutane in both bulk and interfacial regions, but result in a lower interfacial diffusion. In addition, the much stronger interfacial enrichment of surfactants without mixing with H₂SO₄ leads to a worse catalytic performance than BILs. However, the better mixing between BILs and H₂SO₄ leading to better catalytic performance suggests the important role of the BILs acting as phase transfer catalyst for the H₂SO₄-catalyzed alkylation. This study involved multiple reactions and reactants, such as 1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate (cas: 478935-29-4Related Products of 478935-29-4).

1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate (cas: 478935-29-4) belongs to imidazole derivatives. The solubility of imidazoles in ethers is lower than that in alcohols and decreases with increasing chain length of the ethers . In contrast, the solubility of benzimidazoles in alcohols (C3–C6) is higher than in water and generally decreases with a The pharmacophore of imidazole exists in bioactive compounds including amino acids, plant growth regulators and therapeutic agents.n increase of the alkyl chain length of the alcohols. Related Products of 478935-29-4

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Pharmacokinetic evaluation of differential drug release formulations of rabeprazole in dogs was written by Patel, Harilal;Desai, Nirmal;Patel, Prakash;Modi, Nirav;Soni, Krunal;Rameshchandra Patel, Jitendrakumar;Navinbhai Mistry, Gaurav;Patel, Jitendrakumar D.;Chawla, Manish;Srinivas, Nuggehally R.. And the article was included in Drug Development and Industrial Pharmacy in 2019.Quality Control of Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide The following contents are mentioned in the article:

To develop novel dual release prototype capsule formulations of rabeprazole and evaluation of pharmacokinetic properties relative to the reference product (Aciphex) in Beagle dogs. The dual release prototype formulations for rabeprazole were developed by preparing optimized mini-tablets core which was subsequently coated with barrier/enteric coating using standard excipients. Both novel prototype formulations were subjected for in vitro release and assay by HPLC-UV to assess long term stability. Single dose pharmacokinetic study used a single sequence three treatments crossover design. In Periods 1 and 2, four dogs received oral 20 mg dose of two prototype formulations. In Period 3, all dogs recieved a 20 mg oral dose of Aciphex reference product. There was a 1-wk washout time between two successive periods. A quant. anal. of rabeprazole/sulfide metabolite in plasma samples was performed using a validated LC-MS/MS assay and PK parameters were estimated by non-compartmental anal. The stability of the prototype formulations was confirmed over a period of 24 mo with an acceptable assay and dissolution data. One of the novel prototype formulations showed 70% oral bioavailability relative to the reference product. Despite a 30% reduced bioavailability, this showed 1 h delay in peak concentration, longer plasma residence time of rabeprazole (up to 12 h) and longer apparent elimination half-life. The use of a canine model has enabled the selection of a novel dual-release prototype formulation of rabeprazole for further clin. development. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Quality Control of Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. The solubility of imidazoles in ethers is lower than that in alcohols and decreases with increasing chain length of the ethers . In contrast, the solubility of benzimidazoles in alcohols (C3–C6) is higher than in water and generally decreases with a This ring system is present in important biological building blocks, such as histidine and the related hormone histamine.Quality Control of Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem